検索結果 47501 件
| 著者 | 上原 慎也| |
|---|---|
| 発行日 | 2012-08-01 |
| 出版物タイトル | 岡山医学会雑誌 |
| 巻 | 124巻 |
| 号 | 2号 |
| 資料タイプ | 学術雑誌論文 |
| 著者 | 西井 伸洋| |
|---|---|
| 発行日 | 2012-08-01 |
| 出版物タイトル | 岡山医学会雑誌 |
| 巻 | 124巻 |
| 号 | 2号 |
| 資料タイプ | 学術雑誌論文 |
| 著者 | 片岡 祐子| 福島 邦博| 菅谷 明子| 西﨑 和則| |
|---|---|
| 発行日 | 2012-08-01 |
| 出版物タイトル | 岡山医学会雑誌 |
| 巻 | 124巻 |
| 号 | 2号 |
| 資料タイプ | 学術雑誌論文 |
| 著者 | 木村 裕司| 岩川 和秀| 西江 学| 稲垣 優| 岩垣 博巳| |
|---|---|
| 発行日 | 2012-08-01 |
| 出版物タイトル | 岡山医学会雑誌 |
| 巻 | 124巻 |
| 号 | 2号 |
| 資料タイプ | 学術雑誌論文 |
| 著者 | 田辺 俊介| 白川 靖博| 前田 直見| 大原 利章| 野間 和広| 櫻間 教文| 柳井 広之| 山辻 知樹| 猶本 良夫| 藤原 俊義| |
|---|---|
| 発行日 | 2012-08-01 |
| 出版物タイトル | 岡山医学会雑誌 |
| 巻 | 124巻 |
| 号 | 2号 |
| 資料タイプ | 学術雑誌論文 |
| 著者 | 馬 少博| |
|---|---|
| 発行日 | 2012-08-01 |
| 出版物タイトル | 岡山医学会雑誌 |
| 巻 | 124巻 |
| 号 | 2号 |
| 資料タイプ | 学術雑誌論文 |
| 著者 | 中尾 美幸| |
|---|---|
| 発行日 | 2012-08-01 |
| 出版物タイトル | 岡山医学会雑誌 |
| 巻 | 124巻 |
| 号 | 2号 |
| 資料タイプ | 学術雑誌論文 |
| 著者 | 八木 孝仁| |
|---|---|
| 発行日 | 2012-08-01 |
| 出版物タイトル | 岡山医学会雑誌 |
| 巻 | 124巻 |
| 号 | 2号 |
| 資料タイプ | 学術雑誌論文 |
| 著者 | 土井原 博義| |
|---|---|
| 発行日 | 2012-08-01 |
| 出版物タイトル | 岡山医学会雑誌 |
| 巻 | 124巻 |
| 号 | 2号 |
| 資料タイプ | 学術雑誌論文 |
| 著者 | 林 桂一郎| 大守 伊織| 松井 秀樹| |
|---|---|
| 発行日 | 2012-08-01 |
| 出版物タイトル | 岡山医学会雑誌 |
| 巻 | 124巻 |
| 号 | 2号 |
| 資料タイプ | 学術雑誌論文 |
| 著者 | 王 飛霏| 安原 隆雄| 亀田 雅博| 伊達 勲| |
|---|---|
| 発行日 | 2012-08-01 |
| 出版物タイトル | 岡山医学会雑誌 |
| 巻 | 124巻 |
| 号 | 2号 |
| 資料タイプ | 学術雑誌論文 |
| 著者 | 佐々木 剛| 田澤 大| 長谷井 嬢| 国定 俊之| 吉田 晶| 橋本 悠里| 矢野 修也| 吉田 亮介| 宇野 太| 香川 俊輔| 森本 裕樹| 浦田 泰生| 藤原 俊義| 尾﨑 敏文| |
|---|---|
| 発行日 | 2012-08-01 |
| 出版物タイトル | 岡山医学会雑誌 |
| 巻 | 124巻 |
| 号 | 2号 |
| 資料タイプ | 学術雑誌論文 |
| 著者 | 藤村 篤史| 富澤 一仁| 松井 秀樹| |
|---|---|
| 発行日 | 2012-08-01 |
| 出版物タイトル | 岡山医学会雑誌 |
| 巻 | 124巻 |
| 号 | 2号 |
| 資料タイプ | 学術雑誌論文 |
| 著者 | Nagai, Yusuke| |
|---|---|
| 発行日 | 2012-02 |
| 出版物タイトル | Biomaterials |
| 巻 | 33巻 |
| 号 | 4号 |
| 資料タイプ | 学術雑誌論文 |
| JaLCDOI | 10.18926/AMO/48569 |
|---|---|
| フルテキストURL | 66_3_285.pdf |
| 著者 | Mizobuchi, Satoshi| Matsuoka, Yoshikazu| Obata, Norihiko| Kaku, Ryuji| Itano, Yoshitaro| Tomotsuka, Naoto| Taniguchi, Arata| Nishie, Hiroyuki| Kanzaki, Hirotaka| Ouchida, Mamoru| Morita, Kiyoshi| |
| 抄録 | Perioperative beta-blocker administration has recently been recommended for patients undergoing cardiac or other surgery due to the beneficial cardiovascular effects of these agents. In addition, some studies have reported that perioperatively administered beta-blockers also have analgesic effects. In this study, to investigate the antinociceptive effects and the analgesic profile of landiolol, we examined the effects of intrathecal landiolol administration on nociceptive pain behavior and c-fos mRNA expression (a neural marker of pain) in the spinal cord using a rat formalin model. We found that pain-related behavior was inhibited by intrathecal landiolol administration. Moreover, the increase in c-fos mRNA expression on the formalin-injected side was less pronounced in rats administered landiolol than in saline administered controls. Thus, intrathecal administration of landiolol exhibited antinociceptive effects. Further investigation of the antinociceptive mechanism of landiolol is required. |
| キーワード | beta-blocker landiolol formalin pain behavior c-fos |
| Amo Type | Original Article |
| 出版物タイトル | Acta Medica Okayama |
| 発行日 | 2012-06 |
| 巻 | 66巻 |
| 号 | 3号 |
| 出版者 | Okayama University Medical School |
| 開始ページ | 285 |
| 終了ページ | 289 |
| ISSN | 0386-300X |
| NCID | AA00508441 |
| 資料タイプ | 学術雑誌論文 |
| 言語 | 英語 |
| 著作権者 | CopyrightⒸ 2012 by Okayama University Medical School |
| 論文のバージョン | publisher |
| 査読 | 有り |
| PubMed ID | 22729110 |
| Web of Science KeyUT | 000305669700013 |
| JaLCDOI | 10.18926/AMO/48568 |
|---|---|
| フルテキストURL | 66_3_279.pdf |
| 著者 | Nishimura, Mamoru| Nouso, Kazuhiro| Kariyama, Kazuya| Wakuta, Akiko| Kishida, Masayuki| Wada, Nozomu| Higashi, Toshihiro| Yamamoto, Kazuhide| |
| 抄録 | The artificial ascites technique is often used during radiofrequency ablation (RFA) for hepatocellular carcinoma (HCC) treatment because it prevents visceral damage and improves visualization by minimizing interference of the lungs and mesentery. This study determined the efficacy and safety of RFA using the artificial ascites technique in HCC patients. We examined 188 HCC patients who were treated by RFA and fulfilled the Milan criteria. Treatment outcomes (complete ablation rate, local recurrence rate, complication rate, liver function including total bilirubin level, alanine aminotransferase level, albumin level, and prothrombin time) were compared among patients divided into 3 groups based on the volume of artificial ascites injected:GroupⅠ (n＝86), no artificial ascites injected;GroupⅡ (n＝35), ＜1,000ml artificial ascites injected;and Group Ⅲ (n＝67), ＞1,000ml artificial ascites injected. No significant difference was observed in complete ablation or local recurrence rates among the 3 groups, or in the extent of liver function damage after RFA. Artificial ascites disappeared within 7 days; additional diuretics were needed only in 5 (all from Group Ⅲ) of 102 patients. No serious complications such as intestinal perforation or intraperitoneal bleeding were observed. Thus, we found that artificial ascites injection during RFA is effective and safe, and can be used to prevent major procedural complications. |
| キーワード | radiofrequency ablation hepatocellular carcinoma artificial ascites |
| Amo Type | Original Article |
| 出版物タイトル | Acta Medica Okayama |
| 発行日 | 2012-06 |
| 巻 | 66巻 |
| 号 | 3号 |
| 出版者 | Okayama University Medical School |
| 開始ページ | 279 |
| 終了ページ | 284 |
| ISSN | 0386-300X |
| NCID | AA00508441 |
| 資料タイプ | 学術雑誌論文 |
| 言語 | 英語 |
| 著作権者 | CopyrightⒸ 2012 by Okayama University Medical School |
| 論文のバージョン | publisher |
| 査読 | 有り |
| PubMed ID | 22729109 |
| Web of Science KeyUT | 000305669700012 |
| JaLCDOI | 10.18926/AMO/48567 |
|---|---|
| フルテキストURL | 66_3_271.pdf |
| 著者 | Lee, Shin-Wha| Kim, Yong-Man| Kim, Moon-Bo| Kim, Dae-Yeon| Kim, Jong-Hyeok| Nam, Joo-Hyun| Kim, Young-Tak| |
| 抄録 | The choice of chemotherapeutic drugs to treat patients with epithelial ovarian cancer has not depended on individual patient characteristics. We have investigated the correlation between in vitro chemosensitivity, as determined by the histoculture drug response assay (HDRA), and clinical responses in epithelial ovarian cancer. Fresh tissue samples were obtained from 79 patients with epithelial ovarian cancer. The sensitivity of these samples to 11 chemotherapeutic agents was tested using the HDRA method according to established methods, and we analyzed the results retrospectively. HDRA showed that they were more chemosensitive to carboplatin, topotecan and belotecan, with inhibition rates of 49.2%, 44.7%, and 39.7%, respectively, than to cisplatin, the traditional drug of choice in epithelial ovarian cancer. Among the 37 patients with FIGO stage Ⅲ/Ⅳ serous adenocarcinoma who were receiving carboplatin combined with paclitaxel, those with carboplatin-sensitive samples on HDRA had a significantly longer median disease-free interval than patients with carboplatin- resistant samples (23.2 vs. 13.8 months, p＜0.05), but median overall survival did not differ significantly (60.4 vs. 37.3 months, p＝0.621). In conclusion, this study indicates that HDRA could provide useful information for designing individual treatment strategies in patients with epithelial ovarian cancer. |
| キーワード | chemosensitivity carboplatin HDRA (histoculture drug response assay) epithelial ovarian cancer |
| Amo Type | Original Article |
| 出版物タイトル | Acta Medica Okayama |
| 発行日 | 2012-06 |
| 巻 | 66巻 |
| 号 | 3号 |
| 出版者 | Okayama University Medical School |
| 開始ページ | 271 |
| 終了ページ | 277 |
| ISSN | 0386-300X |
| NCID | AA00508441 |
| 資料タイプ | 学術雑誌論文 |
| 言語 | 英語 |
| 著作権者 | CopyrightⒸ 2012 by Okayama University Medical School |
| 論文のバージョン | publisher |
| 査読 | 有り |
| PubMed ID | 22729108 |
| Web of Science KeyUT | 000305669700011 |
| JaLCDOI | 10.18926/AMO/48566 |
|---|---|
| フルテキストURL | 66_3_263.pdf |
| 著者 | Sasaki, Takanori| Kuroda, Masahiro| Katashima, Kazunori| Ashida, Masakazu| Matsuzaki, Hidenobu| Asaumi, Junichi| Murakami, Jun| Ohno, Seiichiro| Kato, Hirokazu| Kanazawa, Susumu| |
| 抄録 | The roles of cell density, extracellular space, intracellular factors, and apoptosis induced by the molecularly targeted drug rituximab on the apparent diffusion coefficient (ADC) values were investigated using bio-phantoms. In these bio-phantoms, Ramos cells (a human Burkittｾs lymphoma cell line) were encapsulated in gellan gum. The ADC values decreased linearly with the increase in cell density, and declined steeply when the extracellular space became less than 4 μm. The analysis of ADC values after destruction of the cellular membrane by sonication indicated that approximately 65% of the ADC values of normal cells originate from the cell structures made of membranes and that the remaining 35% originate from intracellular components. Microparticles, defined as particles smaller than the normal cells, increased in number after rituximab treatments, migrated to the extracellular space and significantly decreased the ADC values of bio-phantoms during apoptosis. An in vitro study using bio-phantoms was conducted to quantitatively clarify the roles of cellular factors and of extracellular space in determining the ADC values yielded by tumor cells and the mechanism by which apoptosis changes those values. |
| キーワード | apparent diffusion coefficient value cell density extracellular space bio-phantom |
| Amo Type | Original Article |
| 出版物タイトル | Acta Medica Okayama |
| 発行日 | 2012-06 |
| 巻 | 66巻 |
| 号 | 3号 |
| 出版者 | Okayama University Medical School |
| 開始ページ | 263 |
| 終了ページ | 270 |
| ISSN | 0386-300X |
| NCID | AA00508441 |
| 資料タイプ | 学術雑誌論文 |
| 言語 | 英語 |
| 著作権者 | CopyrightⒸ 2012 by Okayama University Medical School |
| 論文のバージョン | publisher |
| 査読 | 有り |
| PubMed ID | 22729107 |
| Web of Science KeyUT | 000305669700010 |
| JaLCDOI | 10.18926/AMO/48565 |
|---|---|
| フルテキストURL | 66_3_253.pdf |
| 著者 | Zhang, Kai| Yamamoto, Yumiko| Suzuki, Tomonori| Yokota, Kenji| Ma, Shaobo| Nengah Dwi Fatmawati, Ni| Oguma, Keiji| |
| 抄録 | Cultured Clostridium botulinum strains produce progenitor toxins designated as 12S, 16S, and 19S toxins. The 12S toxin consists of a neurotoxin (NTX, 7S) and a non-toxic non-hemagglutinin (NTNH). The 16S and 19S toxins are formed by conjugation of the 12S toxin with hemagglutinin (HA), and the 19S toxin is a dimer of the 16S toxin. Type A cultures produce all 3 of these progenitor toxins, while type E produces only the 12S toxin. The 7S toxin is cleaved into heavy (H) and light (L) chains by a protease(s) in some strains, and the H chain has 2 domains, the N-terminus (Hn) and C-terminus (Hc). It has been reported that type A toxins bind to the intestinal cells or cultured cells via either HA or Hc. In this study, we investigated the binding of type A and E toxins to Caco-2 cells using Western blot analysis. Both the type E 7S and 12S toxins bound to the cells, with the 7S toxin binding more strongly, whereas, in the type A strain, only the 16S/19S toxins showed obvious binding. Pre-incubation of the type E 7S toxin with IgG against recombinant type E Hc significantly inhibited the 7S toxin binding, indicating that Hc might be a main binding domain of the type E toxin. |
| キーワード | Clostridum botulinum neurotoxins Caco-2 binding Hc |
| Amo Type | Original Article |
| 出版物タイトル | Acta Medica Okayama |
| 発行日 | 2012-06 |
| 巻 | 66巻 |
| 号 | 3号 |
| 出版者 | Okayama University Medical School |
| 開始ページ | 253 |
| 終了ページ | 261 |
| ISSN | 0386-300X |
| NCID | AA00508441 |
| 資料タイプ | 学術雑誌論文 |
| 言語 | 英語 |
| 著作権者 | CopyrightⒸ 2012 by Okayama University Medical School |
| 論文のバージョン | publisher |
| 査読 | 有り |
| PubMed ID | 22729106 |
| Web of Science KeyUT | 000305669700009 |
| 関連URL | http://ousar.lib.okayama-u.ac.jp/metadata/48451 |
| JaLCDOI | 10.18926/AMO/48564 |
|---|---|
| フルテキストURL | 66_3_245.pdf |
| 著者 | Okada, Toshiaki| Takigawa, Nagio| Kishino, Daizo| Katayama, Hideki| Kuyama, Shouichi| Sato, Ken| Mimoto, Junko| Ueoka, Hiroshi| Tanimoto, Mitsune| Kiura, Katsuyuki| |
| 抄録 | Cisplatin is used to treat lung cancer;however, it is also a known carcinogen. Cyclooxygenase-2 (COX-2) inhibitors have been shown to prevent carcinogen-induced experimental tumors. We investigated the effect of a COX-2 inhibitor, celecoxib, on cisplatin-induced lung tumors. One hundred twenty 4-week-old A/J mice were divided into 6 groups:group 1, no treatment;group 2, low-dose celecoxib (150mg/kg);group 3, high-dose celecoxib (1,500mg/kg);group 4, cisplatin alone;group 5, cisplatin plus low-dose celecoxib;and group 6, cisplatin plus high-dose celecoxib. Mice in groups 4-6 were administered cisplatin (1.62mg/kg, i.p.) once a week for 10 weeks between 7 and 16 weeks of age. All mice were sacrificed at week 30. Tumor incidence was 15.8% in group 1, 25% in group 2, 26.3% in group 3, 60% in group 4, 50% in group 5, and 50% in group 6. Tumor multiplicity was 0.2, 0.3, 0.3, 1.3, 1.0, and 0.6 in groups 1-6, respectively. Tumor multiplicity in the cisplatin-treated mice was reduced by celecoxib treatment in a dose-dependent manner (p＜0.05, group 4 vs. group 6). Celecoxib significantly reduced COX-2 expression in cisplatin-induced tumors (p＜0.01, group 4 vs. group 6). |
| キーワード | cisplatin non-small cell lung cancer celecoxib cyclooxygenase-2 chemoprevention |
| Amo Type | Original Article |
| 出版物タイトル | Acta Medica Okayama |
| 発行日 | 2012-06 |
| 巻 | 66巻 |
| 号 | 3号 |
| 出版者 | Okayama University Medical School |
| 開始ページ | 245 |
| 終了ページ | 251 |
| ISSN | 0386-300X |
| NCID | AA00508441 |
| 資料タイプ | 学術雑誌論文 |
| 言語 | 英語 |
| 著作権者 | CopyrightⒸ 2012 by Okayama University Medical School |
| 論文のバージョン | publisher |
| 査読 | 有り |
| PubMed ID | 22729105 |
| Web of Science KeyUT | 000305669700008 |